Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: An application of history-adjusted marginal structural models

Statistics in Medicine

Volumn 31, Issue 5, 2012, Pages 470-488

  Rosthoj S ^a   Keiding, N ^a   Schmiegelow, K ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Childhood acute lymphoblastic leukaemia; Dynamic treatment regimes; History adjusted marginal structural models; Inverse probability of treatment weight estimation

Indexed keywords

DRUG METABOLITE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HISTORY ADJUSTED MARGINAL STRUCTURAL MODEL; HUMAN; INVERSE PROBABILITY OF TREATMENT WEIGHTED ESTIMATION; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; TREATMENT PLANNING;

BIOMETRY; CHILD, PRESCHOOL; CYTOSTATIC AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INFANT; MALE; MODELS, STATISTICAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; TREATMENT FAILURE;

EID: 84856469668     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4393     Document Type: Article

References (24)

1. van der Laan MJ, Petersen ML, Joffe MM. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. The International Journal of Biostatistics 2005;1:Article4, DOI: 10.2202/1557-4679.1003.
2. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, Ohara A, Ohkawa Y, Mori T, Ishimoto K et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. Journal of Clinical Oncology 2000;18:1508-1516.
3. Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Makipernaa A, Rosthøj S, Szumlanski C, Sørensen TM, Weinshilboum R. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Journal of Clinical Oncology 2003;21:1332-1339, DOI:10.1200/JCO.2003.04.039.
4. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Communications in Statistics - Theory and Methods 1994;23:2379-2412.
5. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology 2008;168:656-664, DOI:10.1093/aje/kwn164.
6. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet(British edition) 1994;343:1188-1190, DOI: 10.1016/S0140-6736(94)92400-7.
7. Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. Journal of Clinical Oncology 1995;13:345-351.
8. Robins JM. A new approach to causal inference in mortality studies with sustained exposure periods - application to control of the healthy worker survivor effect. Mathematical Modelling 1986;7:1393-1512, DOI:10.1016/0270-0255(86)90088-6.
9. Robins JM. Addendum to a new approach to causal inference in mortality studies with a sustained exposure period application to control of the healthy worker survivor effect. Computers & Mathematics with Applications 1987;14:923-945, DOI: 10.1016/0898-1221(87)90238-0.
10. Robins JM. Causal inference from complex longitudinal data. Latent Variable Modeling and Applications to Causality 1997;120:69-117.
11. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption?Epidemiology 2009;20:3-5, DOI: 10.1097/EDE.0b013e31818ef366.
12. Mortimer KM, Neugebauer R, van der Laan M, Tager IB. An application of model-fitting procedures for marginal structural models. American Journal of Epidemiology 2005;162:382-388, DOI: 10.1093/aje/kwi208.
13. Tager IB, Haight T, Sternfeld B, Yu Z, van der Laan M. Effects of physical activity and body composition on functional limitation in the elderly: application of the marginal structural model. Epidemiology 2004;15:479-493, DOI:10.1097/01.ede.0000128401.55545.c6.
14. Wang Y, Petersen ML, Bangsberg D, van der Laan M. Diagnosing bias in the inverse-probability-of-treatment-weighted estimator resulting from violation of experimental treatment assignment, U.C. Berkeley Division of Biolstatistics Working Paper Series, 2006. Working paper 211..
15. Robins JM, Hernán MÁ, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
16. Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-adjusted marginal structural models for estimating time-varying effect modification. American Journal of Epidemiology 2007;166:985-993, DOI: 10.1093/aje/kwm232.
17. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. Journal of Epidemiology & Community Health 2006;60:578-586, DOI:10.1136/jech.2004.029496.
18. McCullagh P, Nelder JA. Generalized linear models, Chapman & Hall:London, 1989.
19. Lefebvre G, Delaney JAC, Platt RW. Impact of mis-specification of the treatment model on estimates from a marginal structural model. Statistics in Medicine 2008;27:3629-3642, DOI: 10.1002/sim.3200.
20. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. American Journal of Epidemiology 2004;159:926-934, DOI: 10.1093/aje/kwh131.
21. Rosthøj S, Fullwood C, Henderson R, Stewart S. Estimation of optimal dynamic anticoagulation regimes from observational data: a regret-based approach. Statistics in Medicine 2006;25:4197-4215, DOI: 10.1002/sim.2694.
22. Murphy SA. Optimal dynamic treatment regimes. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2003;65:331-355, DOI:10.1111/1467-9868.00389.
23. Robins JM. Optimal structural nested models for optimal sequential decisions, In Proceedings of the Second Seattle Symposium in Biostatistics: Analysis of Correlated Data, Springer, 2004;189-326.
24. Henderson R, Ansell P, Alshibani D. Regret-regression for optimal dynamic treatment regimes. Biometrics 2010;66:1192-1201, DOI:10.1111/j.1541-0420.2009.01368.x.